HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $60 price target.
July 02, 2024 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $60 price target.
The reiteration of a Buy rating and the maintenance of a $60 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100